Navigation Links
BioElectronics Announces Major Clinical Trials

Breast augmentation and cesarean section trials in conjunction with David

G. Genecov, MD, FACS, FAAP to begin immediately

FREDERICK, Md., May 28 /PRNewswire-FirstCall/ -- BioElectronics Corp. (Pink Sheets: BIEL), the maker of the ActiPatch(TM), a drug free anti- inflammatory patch, with an embedded battery operated microchip delivering continuous pulse therapy specifically designed to speed healing, today announced world renowned plastic surgeon David G. Genecov will develop, institute and complete research studies on post-operative management of breast augmentation and cesarean section procedures. Both double blind randomized studies will be done in conjunction with other leading surgeons, obstetricians and gynecologists under Dr. Genecov's direction and supervision.

"We are very excited about these studies and believe they mark an important turning point for BioElectronics Corporation. The use of our products for post-breast augmentation care is already well established and continues to grow at a rapid pace," commented, Andy Whelan, CEO and President of BioElectronics Corporation. "The completion of a formal study by a surgeon of Dr. Genecov's caliber will further cement our position in this important and growing area. We are also very excited to be starting the trial for post- operative care for cesarean section. According to the National Center for Health Statistics, approximately one third of all babies in the United States are delivered by cesarean section up from less than approximately 20% just a decade ago. We believe this growing market represents a substantial market opportunity for our company."

Dr. David G. Genecov added, "Many general and plastic surgeons are starting to investigate the use of ActiPatch for post-surgical edema and pain control, but there has been little clinical data. We look forward to providing this important data to our colleagues over the coming months in order to determine the best post-operative procedures to assist patients in pain management and recovery."

About BioElectronics Corporation

BioElectronics Corporation is the maker of the ActiPatch(TM). ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for about a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling. ActiPatch is approved by Health Canada for the relief of pain in musculoskeletal complaints. The US government's food and drug administration (FDA) has cleared the use of the product for reducing edema (swelling) following blepharoplasty and the European Union has approved the product as a class two pulsed electromagnetic medical device as have numerous other international record for agencies.

About David G. Genecov, MD FACS FAAP

Dr. David G. Genecov is a native of Dallas, Texas. After finishing his undergraduate degree in the Plan II Honors Program at the University of Texas, he completed his medical training at the University of Texas Health Science Center in San Antonio. Upon completion of his general surgery residency at West Virginia University, Dr. Genecov became board certified in general surgery. He continued his education at Wake Forest University - Bowman Gray School of Medicine and completed his plastic surgery residency. He then completed a fellowship at the International Craniofacial Institute, Dallas, Texas, in Craniomaxillofacial surgery for adults and children with congenital and acquired deformities.

Widely published in both national and international literature, Dr. Genecov has also authored four medical book chapters. Dr. Genecov has received numerous awards for academic excellence, his surgical expertise and philanthropy. Most recently he was named one of the country's top surgeons by the independent Consumer Research Council of America for 2004-2005. He is Certified Member of the American Board of Plastic Surgery, a Certified Member of the American Board of Surgery, a Member of the American Society of Plastic Surgeons, a Member of the American Society of Maxillofacial Surgeons, a Member of the International Society of Craniofacial Surgeons, a Member of the Council of Health Care Advisors, and a Member of the American Academy of Anti-Aging Medicine. More information about Dr. Genecov can be seen at .

Information on ActiPatch and BioElectronics Corporation is available at the following websites:

-- U.S. Consumer

-- Podiatry:

-- Plastic Surgery: and

-- German orthopedic foot & ankle:

-- Italy and Switzerland:

-- Canada:

-- Netherlands:

-- Singapore & Malaysia:

-- BioElectronics Corp:

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies In light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.

Media Contact:

Patricia Baker, The Big Picture Agency LLC

Voice: 413-623-0950 ext. 221, email:

Investor Relations Contact:

Joe Noel, Emerging Growth Research LLP

Voice: 925-922-2560, email:

SOURCE BioElectronics Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
2. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
3. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
4. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
5. BARC Announces Long-Term Cooperation In South African Biobanking for HIV Vaccine Trials
6. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
7. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
8. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
9. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
10. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
11. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
Post Your Comments:
(Date:10/9/2015)... , October 9, 2015 ... die sich einer Kolonoskopie im Rahmen eines ... unterziehen. Die NOCT-Studie bewertete auch die Compliance, ... --> ® ) an erwachsenen Patienten ... eines Screenings, einer beobachtenden oder einer diagnostischen ...
(Date:10/9/2015)... , October 9, 2015 ... (OTCQB: CNBX) has announced its execution of an Intellectual Property ... Liabilities Agreement with Cannabics, Inc. a Delaware Corporation, related party, ... --> --> These ... of the Company, whereby the Research and Development components ...
(Date:10/9/2015)... India , October 9, 2015 ... --> The report ... market and overall status of the ... of guidance and direction for companies ... . ...
Breaking Medicine Technology:
... PRO-DEX, INC. (Nasdaq: PDEX ) invites investors and ... fiscal 2012 first quarter financial results. (Logo:   ... be broadcast live over the internet on Wednesday, November 9, ... and may be accessed by visiting the Company,s website at ...
... VIEW, Calif., Nov. 3, 2011 VIVUS, Inc. (NASDAQ: ... were published in Obesity, the peer-reviewed journal of The ... the investigational drug Qnexa in 1,267 severely obese (BMI >/= 35 ... addition to average weight loss of 14.4% of initial body weight ...
Cached Medicine Technology:
(Date:10/10/2015)... ... ... Isabel Healthcare will participate in the Cerner Health Conference October 11-14, 2015 ... Institute of Medicine’s latest report “Improving Diagnosis in Healthcare”, Isabel Healthcare will be featuring ... and consumers to potentially reduce the chance of error. The report suggests that most ...
(Date:10/9/2015)... ... October 09, 2015 , ... The American Osteopathic Foundation ... Graduate Medical Education J. Michael Finley, DO, as the recipient of the 2015 ... his impact on graduate medical education opportunities for osteopathic residents, and his dedication ...
(Date:10/9/2015)... ... ... A new health tool that helps identify if a sore throat is ... – just in time for the cold and flu season, which the Center for ... the U.S., the real start of cold/flu season is the start of the school ...
(Date:10/9/2015)... ... October 09, 2015 , ... Dentist in Huntington Beach ... system that uses clear, plastic aligners. This alternative to braces has become wildly ... allow patients to complete treatment in privacy. Additionally, Invisalign aligners are removable, so ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... The Asthma ... the US Centers for Disease Control and Prevention (CDC) to improve the knowledge and ... that AAFA has been awarded a project by the CDC and allows AAFA to ...
Breaking Medicine News(10 mins):
... better diagnosis and drug treatments, study says , , WEDNESDAY, ... most common form of mental retardation -- called nonsyndromic ... that may contribute to the condition, new research finds. ... occurs during development of the child and is not ...
... virus strikes healthy kids, and it affects more youngsters than ... It,s called respiratory syncytial virus (RSV), a childhood infection that,s ... and one of every 38 emergency room trips, a new ... for inpatient hospital stays for one out of every 334 ...
... is a statement by Matthew L. Myers, President, ... and President Obama today are delivering a historic ... increasing federal tobacco taxes, including a 62-cent increase ... Children,s Health Insurance Program (SCHIP). This legislation ...
... Feb. 4 , WHAT: , ... event, with members of the cast,of Broadway,s Tony Award-winning best ... February 6, 2009 , WHO: , ... compelling stories of women making,heart-healthy choices and inspiring others with ...
... seeks new ways to prevent and treat chronic diseases such ... be conducted on the benefits of certain foods in reducing ... often cited as being high in antioxidants, which have the ... within the body, reducing the risk of cancer and other ...
... Feb. 4 Erik Olson, director of chemical and food ... the following statement today in response to the introduction of ... , , "In the midst of ... Safety Modernization Act (FSMA) could not be more timely. The ...
Cached Medicine News:
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Pocket-sized instrument with 2.5X magnification....
Pocket-sized instrument. All Keeler otoscopes have bright halogen illumination for clear and accurate visualization of aural canal. Lithium-ion batteries with quick recharge capability. Ring rheos...
Otoscope with 4X magnification lens, swivellable to both sides, with removable cover glass to insert external instruments. Sealed system allowing for pneumatic otoscopy. 2.5V halogen source....
Medicine Products: